Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Burns D, Anokian E, Saunders EJ, Bristow RG, Fraser M, Reimand J, et al. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. Eur Urol. 2022;82(2):201-211.

Guo P, Liu Y, Geng F, Daman AW, Liu X, Zhong L, et al. Publisher Correction: Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability. Nat Cell Biol. 2022;24(2):279.

Linares JF, Cid-Diaz T, Duran A, Osrodek M, Martinez-Ordoñez A, Reina-Campos M, et al. The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. Cell Rep. 2022;39(6):110792.

Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2022;28(1):212.

Hanel W, Lata P, Youssef Y, Tran H, Tsyba L, Sehgal L, et al. A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells. Exp Hematol Oncol. 2022;11(1):40.

Rivera-Cruz G, Boyraz B, Petrozza JC. Reply of the Authors: The Waldo of fibroids under the microscope: fumarate hydratase-deficient leiomyomata. F S Rep. 2022;3(2):174.

Tsui DC, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022;23(2):e99-e103.

Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, et al. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022;20(5):673-685.

Devereaux KA, Souers RJ, Merker JD, Lindeman NI, Graham RP, Hameed MR, et al. Clinical Testing for Tumor Cell-Free DNA. Arch Pathol Lab Med. 2022.

Young A, Bu W, Jiang W, Ku A, Kapali J, Dhamne S, et al. Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022;15(1):3-10.